Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 October 2015 - 25 November 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian cell micronucleus test
Test material
- Reference substance name:
- Triglycerides, C16-18 (even numbered), reaction products with diethylenetriamine
- EC Number:
- 810-543-2
- Cas Number:
- 1618093-67-6
- Molecular formula:
- not applicable
- IUPAC Name:
- Triglycerides, C16-18 (even numbered), reaction products with diethylenetriamine
- Test material form:
- solid: flakes
- Details on test material:
- Amidoamine 2 (UVCB based on hydrogenated tallow not hydrogenated palm oil):
- Name of test material (as cited in study report): FCM (DETA)M C16-18 TLW hydrogenated (Amidoamine 2 (UVCB based on hydrogenated tallow not hydrogenated palm oil))
- Substance type: Amidoamine
- Chemical name (old): Amides, from diethylenetriamine and hydrogenated tallow
- Chemical name (new): Triglycerides, C16-18 (even-numbered), reaction products with diethylenetriamine
- CAS 68920-82-1
- Physical state: pale yellowish solid at 20 °C
- Batch No.: PU22340011
- Expiry date of batch: 21 August 2014
- Purity: 100 % (UVCB)
- Storage condition of test material: Room temperature, protected from light
- Stability: stable under test conditions
Constituent 1
- Specific details on test material used for the study:
- Test item without emulsifier was investigated.
Source substance:
Amidoamine (UVCB)
Pulcra ID: DE07_2014_012_BEL66 (amidoamine without emulsifier)
Former chemical name: Amides, from diethylenetriamine and hydrogenated palm oil
Former CAS No.: 1618093-67-6
New chemical name: Triglycerides, C16-18 (even-numbered), reaction products with diethylenetriamine
Physical state: pale yellowish solid at 20 °C
Batch No.: K8 4309 L481
Expiry date of batch: 09 March 2018
Purity: 100 % (UVCB)
Stability: stable under test conditions
Storage condition of test material: Room temperature, protected from light
Target substance:
Amidoamine 2 (UVCB, low nitrogen):
Former chemical name: Amides, from diethylenetriamine and hydrogenated palm oil
CAS No.: 1618093-67-6
New chemical name: Glycerides, C16-18 (even numbered) and their amidation products with diethylenetriamine
Physical state: pale yellowish solid at 20 °C
Batch No.: PU50070067
Purity: 100 % (UVCB)
Storage condition of test material: Room temperature, protected from light
Stability: stable under test conditions
Method
Species / strain
- Species / strain / cell type:
- lymphocytes: Human
- Details on mammalian cell type (if applicable):
- For each experiment, sufficient whole blood was drawn from the peripheral circulation of a non-smoking volunteer (aged 18-35) who had been previously screened for suitability. The volunteer had not knowingly been exposed to high levels of radiation or hazardous chemicals and had not knowingly recently suffered from a viral infection. The cell-cycle time for the lymphocytes from the donors used in this study was determined using BrdU (bromodeoxyuridine) incorporation to assess the number of first, second and third division metaphase cells and so calculate the average generation time (AGT). The mean value of the AGT for the pool of regular donors used in this laboratory has been determined to be approximately 16 hours under typical experimental exposure conditions.
Preliminary Toxicity Test: male, aged 35 years
Main Experiment: male, aged 29 years
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix
- Test concentrations with justification for top dose:
- Based on the precipitate observations in the solubility test, the maximum dose level selected for the Preliminary Toxicity Test was 320 µg/mL. Since the OECD 473 guideline requires only one precipitating dose level to be tested, irrespective of toxicity it was decided to reduce the maximum dose for the Preliminary Toxicity Test to a level where the lowest precipitating dose level could more easily be identified and exclude the majority of dose levels where precipitate was seen.
The test item was formulated within two hours of it being applied to the test system; the test item formulations were assumed to be stable. - Vehicle / solvent:
- Vehicle and positive controls were used in parallel with the test item.
The vehicle control used was Minimal Essential Medium (Sigma, Batch No. RNBD4261).
Controls
- Untreated negative controls:
- yes
- Remarks:
- The vehicle control used was Minimal Essential Medium.
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- Details on test system and experimental conditions:
- Cells (whole blood cultures) were grown in Eagle's minimal essential medium with HEPES buffer (MEM), supplemented “in-house” with L-glutamine, penicillin/streptomycin, amphotericin B and 10% foetal bovine serum (FBS), at approximately 37 ºC with 5% CO2 in humidified air. The lymphocytes of fresh heparinized whole blood were stimulated to divide by the addition of phytohaemagglutinin (PHA).
- Evaluation criteria:
- Providing that all of the acceptability criteria are fulfilled, a test item can be considered to be clearly negative if, in any of the experimental conditions examined:
1. The number of cells with structural chromosome aberrations in all evaluated dose groups should be within the range of the laboratory historical control data.
2. No toxicologically or statistically significant increase of the number of cells with structural chromosome aberrations is observed following statistical analysis.
3. There is no concentration-related increase at any dose level.
A test item can be classified as genotoxic if:
1. The number of induced structural chromosome aberrations is outside the range of the laboratory historical control data.
2. At least one concentration exhibits a statistically significant increase in the number of cells with structural chromosome aberrations compared to the concurrent negative control.
3. The observed increase in the frequency of cells with structural aberrations is considered to be dose-related.
When all of the above criteria are met, the test item can be considered able to induce chromosomal aberrations in human lymphocytes.
Results and discussion
Test resultsopen allclose all
- Key result
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- with
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- The S9 Microsomal fraction was prepared in-house from male rats induced with Phenobarbitone/β-Naphthoflavone at 80/100 mg/kg/day,
orally, for 3 days prior to preparation on day 4. The S9 homogenate was produced by homogenizing the liver in a 0.15M KCl solution (1g liver to 3 mL KCl) followed by centrifugation at 9000 g. The protein content of the resultant supernatant was adjusted to 20 mg/mL. Aliquots of the supernatant were frozen and stored at approximately -196 °C. Prior to use, each batch of S9 was tested for its capability to activate known mutagens in the Ames
test.
The S9-mix was prepared prior to the dosing of the test cultures and contained the S9 fraction (20% (v/v)), MgCl2 (8mM), KCl (33mM), sodium orthophosphate buffer pH 7.4 (100mM), glucose-6-phosphate (5mM) and NADP (5mM). The final concentration of S9, when dosed at a 10% volume of S9-mix into culture media, was 2%.
Any other information on results incl. tables
Results of Chromosome Aberration Test – Main Experiment 4(20)-hour Exposure Without Metabolic Activation (S9)
Treatment Group |
Replicate |
Mitotic Index (%) |
Number of Cells Scored |
Total Number of Aberrations |
Frequency of Aberrant Cells (%) |
||
|
|
|
|
(+ Gaps) |
(- Gaps) |
(+ Gaps) |
(- Gaps) |
Vehicle Control (MEM) |
A |
3.40 |
150 |
2 |
1 |
2 |
1 |
|
B |
2.90 |
150 |
0 |
0 |
0 |
0 |
|
Total |
(100) |
300 |
2 |
1 |
2 (0.7) |
1 (0.3) |
10 µg/ml |
A |
2.20 |
150 |
0 |
0 |
0 |
0 |
|
B |
2.30 |
150 |
0 |
0 |
0 |
0 |
|
Total | (71) | 300 | 0 | 0 | 0 (0.0) | 0 (0.0) |
20 µg/ml |
A | 3.40 | 150 | 2 | 2 | 2 | 2 |
B | 2.25 | 150 | 3 | 3 | 3 | 3 | |
Total | (90) | 300 | 5 | 5 | 5 (1.7) | 5 (1.7) | |
40 µg/ml |
A | 2.70 | 150 | 2 | 1 | 2 | 1 |
B | 1.45 | 150 | 1 | 1 | 1 | 1 | |
Total | (66) | 300 | 3 | 2 | 3 (1.0) | 2 (0.7) | |
80 µg/ml |
A | 1.50 | 150 | 1 | 1 | 1 | 1 |
B | 5.00 | 150 | 1 | 1 | 1 | 1 | |
Total | (103) | 300 | 2 | 2 | 2 (0.7) | 2 (0.7) | |
Mitomycin C 0.2 µg/ml | A | 1.85 | 35* | 21 | 18 | 18 | 15 |
B | 1.65 | 150 | 20 | 20 | 12 | 12 | |
Total | (56) | 185 | 41 | 38 | 30 (16.2) | 27 (14.6)** |
* Slide evaluation terminated when 15 cells with aberrations (excluding gaps) had been observed
** P < 0.001
Results of Chromosome Aberration Test – Main Experiment 4(20)-hour Exposure With Metabolic Activation (S9)
Treatment Group |
Replicate |
Mitotic Index (%) |
Number of Cells Scored |
Total Number of Aberrations |
Frequency of Aberrant Cells (%) |
||
|
|
|
|
(+ Gaps) |
(- Gaps) |
(+ Gaps) |
(- Gaps) |
Vehicle Control (MEM) |
A |
5.45 |
150 |
1 |
1 |
1 |
1 |
|
B |
4.75 |
150 |
1 |
0 |
1 |
0 |
|
Total |
(100) |
300 |
2 |
1 |
2 (0.7) |
1 (0.3) |
10 µg/ml |
A |
2.40 |
150 |
1 |
1 |
1 |
1 |
|
B |
3.00 |
150 |
1 |
1 |
1 |
1 |
|
Total |
(53) |
300 |
2 |
2 |
2 (0.7) |
2 (0.7) |
20 µg/ml |
A |
4.60 |
150 |
1 |
1 |
1 |
1 |
|
B |
2.10 |
150 |
2 |
1 |
2 |
1 |
|
Total |
(66) |
300 |
3 |
2 |
3 (1.0) |
2 (0.7) |
40 µg/ml |
A |
4.95 |
150 |
2 |
2 |
2 |
2 |
|
B |
2.75 |
150 |
0 |
0 |
0 |
0 |
|
Total |
(75) |
300 |
2 |
2 |
2 (0 .7) |
2 (0.7) |
80 µg/ml |
A |
3.25 |
150 |
1 |
0 |
1 |
0 |
|
B |
5.35 |
150 |
1 |
0 |
1 |
0 |
|
Total |
(84) |
300 |
2 |
0 |
2 (0.7) |
0 (0.0) |
Cyclophosphamide 2.0 µg/ml |
A |
3.75 |
67* |
16 |
16 |
16 |
15 |
|
B |
0.80 |
69* |
15 |
15 |
15 |
15 |
|
Total |
(45) |
136 |
31 |
31 |
31 (22.1) |
30 (22.1)** |
* Slide evaluation terminated when 15 cells with aberrations (excluding gaps) had been observed
** P < 0.001
Results of Chromosome Aberration Test – Main Experiment 24-hour Continuous Exposure Without Metabolic Activation (S9)
Treatment Group |
Replicate |
Mitotic Index (%) |
Number of Cells Scored |
Total Number of Aberrations |
Frequency of Aberrant Cells (%) |
||
|
|
|
(+ Gaps) |
(- Gaps) |
(+ Gaps) |
(- Gaps) |
|
Vehicle Control (MEM) |
A |
8.00 |
150 |
0 |
0 |
0 |
0 |
|
B |
7.40 |
150 |
0 |
0 |
0 |
0 |
|
Total |
(100) |
300 |
0 |
0 |
0 (0.0) |
0 (0.0) |
10 µg/ml |
A |
4.40 |
150 |
4 |
2 |
4 |
2 |
|
B |
3.95 |
150 |
0 |
0 |
0 |
0 |
|
Total |
(100) |
300 |
4 |
2 |
4 (1.3) |
2 (0.7) |
20 µg/ml |
A |
6.80 |
150 |
2 |
0 |
2 |
0 |
|
B |
3.60 |
150 |
1 |
1 |
1 |
1 |
|
Total |
(68) |
300 |
3 |
1 |
3 (1.0) |
1 (0.3) |
40 µg/ml |
A |
6.70 |
150 |
0 |
0 |
0 |
0 |
|
B |
4.15 |
150 |
0 |
0 |
0 |
0 |
|
Total |
(70) |
300 |
0 |
0 |
0 (0.0) |
0 (0.0) |
80 µg/ml |
A |
7.60 |
150 |
0 |
0 |
0 |
0 |
|
B |
6.25 |
150 |
0 |
0 |
0 |
0 |
|
Total |
(90) |
300 |
0 |
0 |
0 (0.0) |
0 (0.0) |
Mitomycin C 0.2 µg/ml |
A |
3.25 |
82* |
17 |
16 |
15 |
15 |
|
B |
2.45 |
150 |
16 |
14 |
15 |
13 |
|
Total |
(37) |
232 |
33 |
30 |
30 (12.9) |
28 (12.1)** |
* Slide evaluation terminated when 15 cells with aberrations (excluding gaps) had been observed
** P < 0.001
Frequency of polyploid cells was 0% in treatment groups ofthe test item.
Historical Aberration Ranges for Vehicle Control Cultures
1. 4(20)-hour exposure without S9
% cells with aberrations (-gaps): 0.48 (mean)
Standard Deviation: 0.56
% cells with polyploids: 0.05 (mean)
Standard Deviation: 0.17
2. 4(20)-hour exposure with S9 (1%)
% cells with aberrations (-gaps): 0.40 (mean)
Standard Deviation: 0.48
% cells with polyploids: 0.02 (mean)
Standard Deviation: 0.11
3. 24-hour exposure without S9
% cells with aberrations (-gaps): 0.44 (mean)
Standard Deviation: 0.52
% cells with polyploids: 0.07 (mean)
Standard Deviation: 0.22
4. 4(20)-hour exposure with S9 (2%)
% cells with aberrations (-gaps): 0.53 (mean)
Standard Deviation: 0.56
% cells with polyploids: 0.09 (mean)
Standard Deviation: 0.24
Historical Aberration Range for Positive Control Cultures
1. 4(20)-hour exposure without S9 (Mitomycin C)
% cells with aberrations (-gaps): 39.86 (mean)
Standard Deviation: 14.04
% cells with polyploids: 0.02 (mean)
Standard Deviation: 0.13
2. 4(20)-hour exposure with S9 (1%) (Cyclophosphamide)
% cells with aberrations (-gaps): 30.66 (mean)
Standard Deviation: 9.65
% cells with polyploids: 0.02 (mean)
Standard Deviation: 0.12
3. 24-hour exposure without S9 (Mitomycin C)
% cells with aberrations (-gaps): 39.09 (mean)
Standard Deviation: 14.57
% cells with polyploids: 0.02 (mean)
Standard Deviation: 0.013
Applicant's summary and conclusion
- Conclusions:
- The test item was considered to be non-clastogenic to human lymphocytes in vitro.
- Executive summary:
The test item was assayed in an in vitro chromosome aberration test using human peripheral lymphocytes both in the presence and absence of metabolic activation by a rat liver post-mitochondrial fraction (S9 mix).
The test was carried out employing 2 exposure times without S9 mix: 4 and 24 hours, and 1 exposure time with S9 mix: 4 hours. The harvesting time was 20 hours after the end of exposure.
The test item was completely dissolved in Minimal Essential Medium. Minimal Essential Medium served as the vehicle control. The concentrations employed were chosen based on the results of a cytotoxicity study. In this preliminary experiment without and with metabolic activation test item concentrations of 1.25 to 320 µg/mL medium were employed.
The maximum dose was reduced to 320 µg/mL based on the precipitate observations in the solubility test and the requirement to test the lowest precipitating dose level.
Hence, 80.0 µg/mL were employed as the top concentration for the mutagenicity tests without and with metabolic activation.
In the absence of S9, mitomycin C (MMC) was used as positive control at 0.2 and 0.05 µg/mL for 4(20)-hour cultures and 24-hour continuous exposure cultures, respectively. It was dissolved in Minimal Essential Medium.
In the presence of S9, cyclophosphamide (CP) was used as positive control at 2 µg/mL. It was dissolved in dimethyl sulphoxide.
All vehicle (MEM) controls had frequencies of cells with aberrations within the range expected for normal human lymphocytes. All the positive control items induced statistically significant increases in the frequency of cells
with aberrations. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item demonstrated no-marked toxicity in the preliminary toxicity test and the maximum mdose level selected for the main test was based on the lowest precipitating dose level. The test item did not induce any statistically significant increases in the frequency of cells with aberrations, using a dose range that included a dose level that was the lowest precipitating dose
level.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.